Overview

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Status:
Completed
Trial end date:
2021-01-06
Target enrollment:
Participant gender:
Summary
Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Azura Ophthalmics
Collaborator:
The University of New South Wales